The recent approval of Wegovy, a once-daily oral semaglutide tablet, by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has raised several concerns among healthcare professionals and policymakers. While the medication offers a new treatment option for adults with obesity or overweight conditions, its introduction warrants careful consideration.
Clinical trials have shown that participants can achieve an average weight loss of approximately 14% over 64 weeks when combining Wegovy with a reduced-calorie diet and increased physical activity. However, the long-term safety and efficacy of the oral formulation remain subjects of ongoing research. The injectable version of semaglutide has been associated with side effects such as nausea, vomiting, and abdominal discomfort, and it is unclear whether the oral version will present similar or different side effects.
The availability of Wegovy through private prescriptions raises questions about equity and access to healthcare. The cost of the medication has not yet been finalized, but it is anticipated to be more affordable than the injectable version, which typically costs between £30 and £300 per month, depending on the dose and length of prescription. Despite this, the expense may still be prohibitive for some individuals, potentially leading to disparities in access and treatment outcomes.